IP
Innate Pharma S.A.
IPHA · NASDAQ
$1.90 +0.53% (+$0.01)
1M -15.93%
Market Cap 156.3M €
P/E Ratio -
Div. Yield -
ROE 933.18%
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 56.07x
PEG N/A
P/B N/A
Growth
0 /100
Declining Rev. growth 63.58%
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Net margin 1,764.51%
Op. margin 1,916.94%
FCF margin 1,823.01%
Quality
1 /100
Poor ROE 933.18%
ROA 78.44%
Asset turnover 0.04x
Debt
24 /100
High Int. coverage -110.77x
Current ratio 1.27x
Net debt/EBITDA N/A
Stability
28 /100
Unstable Rev. volatility 38.58%
EPS volatility 364.59%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre IPHA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Jonathan E. Dickinson
Employees
163
Headquarters
Marseille